BRPI0812178A2 - método para detecção e discriminação simultânea de infecções bacterianas, fúngicas, parasitárias e virais no olho e sistema nervoso central - Google Patents
método para detecção e discriminação simultânea de infecções bacterianas, fúngicas, parasitárias e virais no olho e sistema nervoso central Download PDFInfo
- Publication number
- BRPI0812178A2 BRPI0812178A2 BRPI0812178-8A BRPI0812178A BRPI0812178A2 BR PI0812178 A2 BRPI0812178 A2 BR PI0812178A2 BR PI0812178 A BRPI0812178 A BR PI0812178A BR PI0812178 A2 BRPI0812178 A2 BR PI0812178A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- group
- dna sequence
- sample
- detection
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 86
- 238000000034 method Methods 0.000 title claims abstract description 51
- 230000001580 bacterial effect Effects 0.000 title abstract description 20
- 230000002538 fungal effect Effects 0.000 title abstract description 14
- 210000003169 central nervous system Anatomy 0.000 title abstract description 12
- 208000036142 Viral infection Diseases 0.000 title abstract description 8
- 208000035143 Bacterial infection Diseases 0.000 title abstract description 6
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract description 6
- 206010017533 Fungal infection Diseases 0.000 title abstract description 5
- 208000031888 Mycoses Diseases 0.000 title abstract description 5
- 208000030852 Parasitic disease Diseases 0.000 title abstract description 4
- 230000009385 viral infection Effects 0.000 title description 6
- 230000003071 parasitic effect Effects 0.000 title description 2
- 244000052769 pathogen Species 0.000 claims abstract description 105
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 48
- 208000015181 infectious disease Diseases 0.000 claims abstract description 35
- 208000001860 Eye Infections Diseases 0.000 claims abstract description 24
- 238000012360 testing method Methods 0.000 claims abstract description 17
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 10
- 238000003752 polymerase chain reaction Methods 0.000 claims description 107
- 239000000523 sample Substances 0.000 claims description 93
- 108020004414 DNA Proteins 0.000 claims description 72
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 71
- 241000700584 Simplexvirus Species 0.000 claims description 60
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 241000894006 Bacteria Species 0.000 claims description 52
- 206010014801 endophthalmitis Diseases 0.000 claims description 43
- 238000007403 mPCR Methods 0.000 claims description 43
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 24
- 239000004677 Nylon Substances 0.000 claims description 24
- 229920001778 nylon Polymers 0.000 claims description 24
- 238000009396 hybridization Methods 0.000 claims description 23
- 241000701022 Cytomegalovirus Species 0.000 claims description 22
- 206010046851 Uveitis Diseases 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 20
- 241000233866 Fungi Species 0.000 claims description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 15
- 241000186365 Mycobacterium fortuitum Species 0.000 claims description 15
- 206010038910 Retinitis Diseases 0.000 claims description 15
- 238000004925 denaturation Methods 0.000 claims description 15
- 230000036425 denaturation Effects 0.000 claims description 15
- 239000011159 matrix material Substances 0.000 claims description 15
- 241000701161 unidentified adenovirus Species 0.000 claims description 15
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 14
- 206010014599 encephalitis Diseases 0.000 claims description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 230000003321 amplification Effects 0.000 claims description 13
- 210000001742 aqueous humor Anatomy 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 12
- 230000002441 reversible effect Effects 0.000 claims description 12
- 241000186359 Mycobacterium Species 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 239000003298 DNA probe Substances 0.000 claims description 9
- 201000009906 Meningitis Diseases 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 239000003999 initiator Substances 0.000 claims description 9
- 239000007790 solid phase Substances 0.000 claims description 9
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 108020003215 DNA Probes Proteins 0.000 claims description 7
- 206010023332 keratitis Diseases 0.000 claims description 7
- 201000011475 meningoencephalitis Diseases 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000002096 quantum dot Substances 0.000 claims description 6
- 206010038915 Retinitis viral Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000002458 infectious effect Effects 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 208000020154 Acnes Diseases 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 4
- 239000012807 PCR reagent Substances 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 201000009950 chronic meningitis Diseases 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 238000009595 pap smear Methods 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 210000004915 pus Anatomy 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims 4
- 108020004635 Complementary DNA Proteins 0.000 claims 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 3
- 241000758739 Toxops Species 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 238000010804 cDNA synthesis Methods 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 238000007796 conventional method Methods 0.000 claims 3
- 210000003567 ascitic fluid Anatomy 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 238000011835 investigation Methods 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 208000005228 Pericardial Effusion Diseases 0.000 claims 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 1
- 206010064948 Viral rhinitis Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000004912 pericardial fluid Anatomy 0.000 claims 1
- 210000004910 pleural fluid Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 238000011121 vaginal smear Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 14
- 208000011323 eye infectious disease Diseases 0.000 abstract description 14
- 231100000676 disease causative agent Toxicity 0.000 abstract description 6
- 244000045947 parasite Species 0.000 abstract description 6
- 206010021888 Nervous system infections Diseases 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 description 54
- 108091093088 Amplicon Proteins 0.000 description 46
- 239000000047 product Substances 0.000 description 29
- 102000042567 non-coding RNA Human genes 0.000 description 27
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 22
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 21
- 241000606153 Chlamydia trachomatis Species 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 18
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 18
- 108700022487 rRNA Genes Proteins 0.000 description 18
- 208000007514 Herpes zoster Diseases 0.000 description 17
- 241000223997 Toxoplasma gondii Species 0.000 description 15
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 206010010741 Conjunctivitis Diseases 0.000 description 13
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 229940038705 chlamydia trachomatis Drugs 0.000 description 13
- 108091027963 non-coding RNA Proteins 0.000 description 12
- 108020004465 16S ribosomal RNA Proteins 0.000 description 11
- 241000187478 Mycobacterium chelonae Species 0.000 description 11
- 238000011109 contamination Methods 0.000 description 11
- 241000186427 Cutibacterium acnes Species 0.000 description 10
- 241000223996 Toxoplasma Species 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 229940055019 propionibacterium acne Drugs 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108010009924 Aconitate hydratase Proteins 0.000 description 7
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 7
- 108090000669 Annexin A4 Proteins 0.000 description 7
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 7
- 208000014912 Central Nervous System Infections Diseases 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 101900312130 Human cytomegalovirus Envelope glycoprotein O Proteins 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 108010006785 Taq Polymerase Proteins 0.000 description 7
- 239000000356 contaminant Substances 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 201000008827 tuberculosis Diseases 0.000 description 7
- 102100034612 Annexin A4 Human genes 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 6
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000006740 morphological transformation Effects 0.000 description 6
- 102000013415 peroxidase activity proteins Human genes 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241001529453 unidentified herpesvirus Species 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101150043982 44 gene Proteins 0.000 description 5
- 101150015144 88 gene Proteins 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 208000025222 central nervous system infectious disease Diseases 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000005382 thermal cycling Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 101150084750 1 gene Proteins 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- 241001112695 Clostridiales Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000002944 PCR assay Methods 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 3
- 101150042514 B1 gene Proteins 0.000 description 3
- 201000006082 Chickenpox Diseases 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 108020001027 Ribosomal DNA Proteins 0.000 description 3
- 206010046980 Varicella Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000003771 laboratory diagnosis Methods 0.000 description 3
- 238000011005 laboratory method Methods 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 101150072531 10 gene Proteins 0.000 description 2
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 2
- 101150076076 64 gene Proteins 0.000 description 2
- 102000009836 Aconitate hydratase Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108700003860 Bacterial Genes Proteins 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 208000001351 Epiretinal Membrane Diseases 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 101710171457 Glycoprotein O Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000031471 Macular fibrosis Diseases 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 206010071401 Mycobacterium chelonae infection Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 101150029857 23 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010057854 Cerebral Toxoplasmosis Diseases 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015939 Eye infection toxoplasmal Diseases 0.000 description 1
- 108020000949 Fungal DNA Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010027259 Meningitis tuberculous Diseases 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 206010064997 Necrotising retinitis Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101150101223 ORF29 gene Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010037569 Purulent discharge Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 101710192189 Ribonuclease 1 Proteins 0.000 description 1
- 102100039832 Ribonuclease pancreatic Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010090851 Simplexvirus DNA polymerase Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000022971 Tuberculous meningitis Diseases 0.000 description 1
- 101150098546 UL88 gene Proteins 0.000 description 1
- 206010071005 Viral uveitis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940091179 aconitate Drugs 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 101150013736 gyrB gene Proteins 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 208000024697 human cytomegalovirus infection Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000006420 ocular toxoplasmosis Diseases 0.000 description 1
- 208000008940 ocular tuberculosis Diseases 0.000 description 1
- 101150040063 orf gene Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/101—Temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2561/00—Nucleic acid detection characterised by assay method
- C12Q2561/113—Real time assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1178/DEL/2007 | 2007-06-01 | ||
| IN1178DE2007 | 2007-06-01 | ||
| PCT/IN2008/000334 WO2008146306A2 (en) | 2007-06-01 | 2008-05-27 | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0812178A2 true BRPI0812178A2 (pt) | 2021-05-04 |
Family
ID=39831681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0812178-8A BRPI0812178A2 (pt) | 2007-06-01 | 2008-05-27 | método para detecção e discriminação simultânea de infecções bacterianas, fúngicas, parasitárias e virais no olho e sistema nervoso central |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8465951B2 (enExample) |
| EP (1) | EP2155909B1 (enExample) |
| JP (2) | JP5718049B2 (enExample) |
| KR (1) | KR101866766B1 (enExample) |
| CN (2) | CN104313180B (enExample) |
| AR (2) | AR066825A1 (enExample) |
| AU (1) | AU2008256216B2 (enExample) |
| BR (1) | BRPI0812178A2 (enExample) |
| CA (1) | CA2689306C (enExample) |
| IL (1) | IL202459A (enExample) |
| MY (2) | MY150954A (enExample) |
| NZ (1) | NZ582232A (enExample) |
| TW (1) | TWI410491B (enExample) |
| WO (1) | WO2008146306A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661474B1 (fr) | 1990-04-25 | 1992-06-12 | Valeo | Double volant amortisseur de torsion pour moteur a combustion interne. |
| JP2788853B2 (ja) | 1994-02-14 | 1998-08-20 | 株式会社エクセディ | ダンパー装置 |
| CA2689306C (en) * | 2007-06-01 | 2019-01-15 | Council Of Scientific & Industrial Research | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system |
| US20120040349A1 (en) * | 2009-05-12 | 2012-02-16 | Piia Von Lode | Method for detecting nucleic acids |
| EP2270202A1 (en) * | 2009-07-03 | 2011-01-05 | John Ikonomopoulos | Mycobacterial detection |
| EP3882633A1 (en) | 2012-02-09 | 2021-09-22 | MeMed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| WO2013148868A1 (en) * | 2012-03-30 | 2013-10-03 | Intelligent Medical Devices, Inc. | Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of herpes simplex virus |
| CN103045761B (zh) * | 2012-12-14 | 2016-01-20 | 山东省眼科研究所 | 用于检测感染性眼病致病微生物的试剂盒及检测方法 |
| WO2014186874A1 (en) | 2013-05-23 | 2014-11-27 | Yyz Pharmatech, Inc. | Methods and compositions for enzyme linked immuno and hybridization mass spectrometric assay |
| CN111624346A (zh) | 2014-08-14 | 2020-09-04 | 米密德诊断学有限公司 | 用于预测及/或决定预后的套组 |
| CN204050005U (zh) * | 2014-09-09 | 2014-12-31 | 赵潺 | 一次性负压前房穿刺针 |
| US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| US9828627B2 (en) * | 2014-11-05 | 2017-11-28 | Illumina Cambridge Limited | Reducing DNA damage during sample preparation and sequencing using siderophore chelators |
| EP3225696B1 (en) * | 2014-11-19 | 2020-06-03 | Otsuka Pharmaceutical Co., Ltd. | Primer set and method for amplifying exons of pkd1 gene and pkd2 gene |
| CA2968650A1 (en) | 2014-12-11 | 2016-06-16 | Memed Diagnostics Ltd. | Marker combinations for diagnosing infections and methods of use thereof |
| KR101521409B1 (ko) * | 2015-01-15 | 2015-05-18 | 경북대학교 산학협력단 | 진균성 및 아메바성 각막염의 원인체를 동시에 검출할 수 있는 다중 중합효소 연쇄반응 프라이머 세트 및 이를 이용한 각막염 유발균 검출 방법 |
| EP3154439A1 (en) * | 2015-05-19 | 2017-04-19 | Yaya Diagnostics GmbH | Means and methods for the enrichment of nucleic acids |
| US12338497B2 (en) | 2016-03-03 | 2025-06-24 | Memed Diagnostics Ltd. | Analyzing RNA for diagnosing infection type |
| CN108699583B (zh) | 2016-03-03 | 2022-11-01 | 米密德诊断学有限公司 | 用于区分细菌和病毒感染的rna决定子 |
| CN106167833B (zh) * | 2016-05-20 | 2019-09-20 | 南方医科大学 | 一种同时检测8种虫媒脑炎病毒的rt-pcr引物和探针组合及试剂盒 |
| EP3482201B1 (en) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| WO2018011795A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| EP3519833B1 (en) | 2016-09-29 | 2024-08-14 | MeMed Diagnostics Ltd. | Methods of prognosis and treatment |
| US11353456B2 (en) | 2016-09-29 | 2022-06-07 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification for appendicitis |
| CN106834548B (zh) * | 2017-03-30 | 2020-03-27 | 广州基迪奥生物科技有限公司 | 一种常见眼内感染病毒多重实时荧光pcr检测试剂盒 |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| US12195810B2 (en) | 2017-12-22 | 2025-01-14 | Massachusetts Eye And Ear Infirmary | Comprehensive microbial panel for molecular diagnosis of eye infections |
| KR102297545B1 (ko) * | 2020-02-06 | 2021-09-02 | 경희대학교 산학협력단 | 코리스메이트 뮤테이즈 단백질 항체를 포함하는 가시아메바성 각막염의 감별 진단용 조성물 및 이를 이용한 가시아메바성 각막염 진단 키트 |
| CN111763767A (zh) * | 2020-06-04 | 2020-10-13 | 上海捷诺生物科技有限公司 | 中枢神经系统感染病原体检测试剂盒及其应用 |
| CN113201599B (zh) * | 2021-06-03 | 2023-03-31 | 北京大学人民医院 | 一种基于PCR和nanopore测序检测脑脊液感染哪些病原体的方法 |
| CN114277167A (zh) * | 2021-12-31 | 2022-04-05 | 杭州千基生物科技有限公司 | 一种用于细菌性肠道病原体的量子点核酸检测的试剂盒 |
| CN114891870A (zh) * | 2022-06-26 | 2022-08-12 | 杭州奥明医学检验实验室有限公司 | 一种基于mNGS检测致癌病原体的方法、系统及装置 |
| CN116144811B (zh) * | 2022-12-21 | 2024-02-20 | 迪飞医学科技(南京)有限公司 | 用于检测脑脊液病原的多重引物组、方法和试剂盒 |
| CN116121428A (zh) * | 2023-03-17 | 2023-05-16 | 郑州安图生物工程股份有限公司 | 引物探针组合及试剂盒 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639871A (en) | 1988-09-09 | 1997-06-17 | Roche Molecular Systems, Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| JPH10323189A (ja) * | 1997-05-23 | 1998-12-08 | Toyobo Co Ltd | 抗酸菌属細菌の検出または菌種同定用オリゴヌクレオチドおよびその用途 |
| US6514694B2 (en) * | 1997-12-19 | 2003-02-04 | Heska Corporation | Methods for the detection of encysted parasites |
| KR100316095B1 (ko) * | 1999-05-29 | 2001-12-13 | 김정준 | 마이코박테리아 균종 동정용 올리고뉴클레오티드 |
| US20040121335A1 (en) | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections |
| US20030027135A1 (en) | 2001-03-02 | 2003-02-06 | Ecker David J. | Method for rapid detection and identification of bioagents |
| JP2003144153A (ja) * | 2001-11-09 | 2003-05-20 | Gifu Univ | 遺伝子検出方法、遺伝子検出用プライマー、ｄｎａマイクロアレイ及び遺伝子検出用キット |
| CN1329523C (zh) * | 2002-08-09 | 2007-08-01 | 中国人民解放军基因工程研究所 | 一种限制性荧光标记方法 |
| CN1508264A (zh) * | 2002-12-18 | 2004-06-30 | 云南大学 | 一种临床感染性疾病基因芯片诊断方案 |
| US7932093B2 (en) | 2003-05-07 | 2011-04-26 | Coris Bioconcept Sprl | One step oligochromatographic device and method of use |
| CN1195070C (zh) * | 2003-05-09 | 2005-03-30 | 陶开华 | 一种检测多种传染病的检测型基因芯片及应用 |
| CA2562775C (en) * | 2004-04-07 | 2015-08-04 | Access Bio, Inc. | Nucleic acid detection system |
| JP2006129810A (ja) * | 2004-11-08 | 2006-05-25 | Canon Inc | 感染症起炎菌検出用プローブセット及び担体及び遺伝子検査方法 |
| PL1845158T3 (pl) * | 2005-01-31 | 2014-02-28 | Yakult Honsha Kk | Sposób ilościowego oznaczania drobnoustroju ukierunkowanego na rRNA |
| EP1951888B1 (en) * | 2005-11-09 | 2012-09-05 | PrimeraDx, Inc. | Multiplexed quantitative detection of pathogens |
| CN1896284B (zh) * | 2006-06-30 | 2013-09-11 | 博奥生物有限公司 | 一种鉴别等位基因类型的方法 |
| CN1995387B (zh) * | 2006-11-07 | 2010-06-23 | 亚能生物技术（深圳）有限公司 | 分枝杆菌菌种鉴定基因芯片检测系统 |
| CA2689306C (en) * | 2007-06-01 | 2019-01-15 | Council Of Scientific & Industrial Research | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system |
-
2008
- 2008-05-27 CA CA2689306A patent/CA2689306C/en not_active Expired - Fee Related
- 2008-05-27 MY MYPI20095120 patent/MY150954A/en unknown
- 2008-05-27 BR BRPI0812178-8A patent/BRPI0812178A2/pt not_active Application Discontinuation
- 2008-05-27 NZ NZ582232A patent/NZ582232A/en not_active IP Right Cessation
- 2008-05-27 KR KR1020097027361A patent/KR101866766B1/ko not_active Expired - Fee Related
- 2008-05-27 MY MYPI2013004723A patent/MY163053A/en unknown
- 2008-05-27 EP EP08763747.6A patent/EP2155909B1/en not_active Not-in-force
- 2008-05-27 JP JP2010509951A patent/JP5718049B2/ja not_active Expired - Fee Related
- 2008-05-27 WO PCT/IN2008/000334 patent/WO2008146306A2/en not_active Ceased
- 2008-05-27 CN CN201410521073.5A patent/CN104313180B/zh not_active Expired - Fee Related
- 2008-05-27 CN CN200880000035.8A patent/CN101541979B/zh not_active Expired - Fee Related
- 2008-05-27 AU AU2008256216A patent/AU2008256216B2/en not_active Ceased
- 2008-05-27 US US12/602,564 patent/US8465951B2/en not_active Expired - Fee Related
- 2008-05-29 TW TW097119896A patent/TWI410491B/zh not_active IP Right Cessation
- 2008-06-02 AR ARP080102330A patent/AR066825A1/es active IP Right Grant
-
2009
- 2009-12-01 IL IL202459A patent/IL202459A/en not_active IP Right Cessation
-
2013
- 2013-03-18 US US13/845,925 patent/US9777339B2/en not_active Expired - Fee Related
-
2014
- 2014-07-04 JP JP2014138799A patent/JP5927243B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-23 US US15/467,748 patent/US10584392B2/en not_active Expired - Fee Related
-
2018
- 2018-01-25 AR ARP180100170A patent/AR110776A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0812178A2 (pt) | método para detecção e discriminação simultânea de infecções bacterianas, fúngicas, parasitárias e virais no olho e sistema nervoso central | |
| US20240026467A1 (en) | Detection of methicillin-resistant staphylococcus aureus in biological samples | |
| Sun et al. | Detection and genotyping of human herpes simplex viruses in cutaneous lesions of erythema multiforme by nested PCR | |
| HK1217515A1 (zh) | 快速并灵敏基因型鉴定及核酸检测 | |
| US20090258342A1 (en) | Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1 | |
| JP2000511777A (ja) | クラミジア・ニューモニエ検出用核酸プライマーおよびプローブ | |
| CN114672592A (zh) | 一种用于异种移植供体猪多重病毒实时荧光检测的特异性引物、探针和试剂盒 | |
| KR20060100339A (ko) | 다중-중합효소연쇄반응에 의한 성전파질환 원인균 검출을위한 신규한 유형 특이적 프라이머와 이를 이용한 검출방법 | |
| Matthews et al. | Semiquantitative polymerase chain reaction enzyme immunoassay for the diagnosis of pertussis | |
| US20240209464A1 (en) | Pathogen Detection From Urine Analyte in All Gender Patients | |
| HK1133282A (en) | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system | |
| HK1206396B (en) | A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system | |
| US20230287523A1 (en) | Sars-cov-2 rapid sequence-based diagnostic assay with sensors of immune activation and the viral microbiota | |
| CN115820935A (zh) | 猴痘病毒检测靶标的应用及猴痘病毒检测组合物、试剂盒 | |
| Matthews-Greer et al. | Validation of the Roche COBAS AmplicorTM System for Chlamydia trachomatis | |
| CN116287444A (zh) | 检测猴痘病毒的组合物、试剂盒、方法及其用途 | |
| TR2023019504A1 (tr) | Ci̇nsel yolla bulaşan enfeksi̇yonlarina (cybe) sebep olan bakteri̇, vi̇rüs mantar ve protozoa gi̇bi̇ patojenleri̇n tanisi i̇çi̇n bi̇leşenler ve yöntemler | |
| JP2003315339A (ja) | ヒトパルボウイルス感染症の診断方法及び同方法を用いる慢性関節リウマチの診断方法 | |
| Hashemzadeh | Investigating the Role of Adenovirus, Herpes Simplex 1, 2, and Varicella Zoster Virus in Incidence of Conjunctivitis in Tehran, Iran |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |